Why RejuvXO?

RejuvXO is the first ever in-device exosome system for medical spas and medical clinics. 

Exosome therapies do not have FDA approval for injection or other systemic use. Many medical practices will typically provide a service like laser or microneedling and then place exosomes on top of the skin after, hoping it will be effective while also taking the risk of applying a 361 product which can carry legal risks. RejuvXO allows for providers to simply use the needle-free device with the exosomes inside, providing a much better user and patient experience. 

Not only is the device needle-free while still providing similar benefits as those achieved with microneedling, the exosomes are derived from the only 351A filed product in the United States. Our exosomes are pure and potent and uniquely derived from Wharton Jelly.

Wharton's Jelly exosomes have been studied for their unique advantages, including a more ethically sourced origin, less immunogenicity, more longevity, better proliferative capacity and more robust mesenchymal stem cells (MSCs) with higher regenerative potential compared to other sources like adult MSCs. They carry specific beneficial, bioactive, biomolecules, such as high fibrinogen content and have been studied for their wound healing and keratinocyte migration as well as studied for their potent immunomodulatory and regenerative effects for a variety of therapeutic applications. 

Exosomes are not stem cells. Our products are cell free and don't carry vaccines or diseases. Each vial carries 5B verified exosomes, and 100B per package of 20. 

RejuvXO is for purchase by medical providers with an NPI only.*